Robert Barrie
Reporter at Medical Device Network
Reporter at Clinical Trials Arena
Healthcare reporter at GlobalData
Articles
-
4 days ago |
pharmaceutical-technology.com | Robert Barrie
Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two deaths. Shares in the French vaccine maker have slid over the past few days following the start of the investigations. Image credit: Shutterstock/ Ink Drop.
-
6 days ago |
medicaldevice-network.com | Robert Barrie
US-based MicroTransponder has reported positive long-term results for stroke patients who received the company’s paired vagus nerve stimulation (VNS) therapy. The data, published in the medical journal Stroke, demonstrated significant and meaningful clinical improvements that lasted a year. Paired VNS is a therapy that combines electrical stimulation with rehabilitation training.
-
6 days ago |
businessandamerica.com | Robert Barrie
Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science companies. The funds will be allocated in the latest cycle of the Vivo Opportunity Fund, an evergreen public pot that runs in three-year investment cycles. Unlike traditional funds with a fixed lifespan, evergreen investments occur over periodic intervals.
-
1 week ago |
pharmaceutical-technology.com | Robert Barrie
Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023. Bavarian Nordic has recently secured had key vaccine approvals for chikungunya virus and mpox/smallpox. Image credit: Shutterstock / Anne Czichos. Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024.
-
1 week ago |
medicaldevice-network.com | Robert Barrie
A new AI model will be trained on a large set of NHS data in hopes of identifying early interventions for patient care. The generative AI model, called Foresight, is being trained on de-identified data from 57 million people in England as part of a pilot study conducted by University College London (UCL) and King’s College London (KCL). De-identified data is data in which personal information has been stripped away, meaning it is not possible to link back to an individual, ensuring privacy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 42
- Tweets
- 30
- DMs Open
- Yes
RT @newscientist: Ants and other insects are capable of astounding navigational feats. Perhaps an appreciation of this could aid conservati…
Have a read of my article that reports on new hopes for a pancreatic cancer vaccine. It was also picked up by LinkedIn News on its top stories page! #PancreaticCancer #mRNAVaccine https://t.co/CqfTJM8YMi
Great meeting with Grigorij Sutov of Genie Biotech EU discussing the difference in funding opportunities between Lithuania and Britain #biotech #lifesciences
